Market Overview

Sarepta Therapeutics Gives Up Gains Following Notable Tweet


Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) spiked higher on heavy volume and hit an intra-day high of $15.74 Tuesday afternoon.

Sarepta's gain was short-lived as the stock quickly gave up all gains and was trading lower by more than 2 percent mid-Tuesday afternoon.

Investors and traders likely reacted to a Tweet made by Adam Feuerstein, a notable biotech analyst and contributor to The Street.

Feuerstein followed up with an article on The Street in which he suggested there is still "hope" that Sarepta could receive a favorable FDA ruling.

The biotech pro pointed out a paragraph inside an "obscure FDA guidance document" which provides hope that the ongoing regulatory review of its eteplirsen for the treatment of Duchenne muscular dystrophy could see approval.

"An interpretation of this FDA document suggests the eteplirsen review period was extended by three months from February to May because new clinical data submitted by Sarepta in January addressed the agency's concerns sufficiently to allow the drug to be approved," Feuerstein wrote.

However, Feuerstein added that "nothing involving the FDA and the drug-review process is definitive." Nevertheless, there is still a glimmer of hope - "perhaps more than many investors realize given the steep decline in the value of Sarepta's stock price since November."

Latest Ratings for SRPT

Jul 2019MaintainsOverweight
Jul 2019MaintainsOutperform
May 2019MaintainsBuy

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Adam Feuerstein Duchenne Muscular Dystrophy eteplirsenAnalyst Color FDA Intraday Update Analyst Ratings Movers


Related Articles (SRPT)

View Comments and Join the Discussion!

Latest Ratings

View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at

Mid-Afternoon Market Update: Fitbit Drops On Weak Forecast; MRC Global Shares Surge

Bridging The China-US Divide At The ContinuumSF Credit Conference